The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Urological Cancer Drugs Market Research Report 2025
Synopsis
The global Urological Cancer Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Urological Cancer Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Urological Cancer Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Urological Cancer Drugs include Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation and Dendreon Corporation, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Urological Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Urological Cancer Drugs.
Report Scope
The Urological Cancer Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Urological Cancer Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Urological Cancer Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A
Tolmar Inc
Segment by Type
Tablets
Injection
Segment by Application
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Urological Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Urological Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Urological Cancer Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Urological Cancer Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Urological Cancer Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Urological Cancer Drugs include Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation and Dendreon Corporation, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Urological Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Urological Cancer Drugs.
Report Scope
The Urological Cancer Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Urological Cancer Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Urological Cancer Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A
Tolmar Inc
Segment by Type
Tablets
Injection
Segment by Application
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Urological Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Urological Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Urological Cancer Drugs Market Overview
1.1 Product Overview and Scope of Urological Cancer Drugs
1.2 Urological Cancer Drugs Segment by Type
1.2.1 Global Urological Cancer Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Tablets
1.2.3 Injection
1.3 Urological Cancer Drugs Segment by Application
1.3.1 Global Urological Cancer Drugs Market Value by Application: (2024-2030)
1.3.2 Prostate Cancer
1.3.3 Bladder Cancer
1.3.4 Kidney Cancer
1.3.5 Testicular Cancer
1.3.6 Others
1.4 Global Urological Cancer Drugs Market Size Estimates and Forecasts
1.4.1 Global Urological Cancer Drugs Revenue 2019-2030
1.4.2 Global Urological Cancer Drugs Sales 2019-2030
1.4.3 Global Urological Cancer Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Urological Cancer Drugs Market Competition by Manufacturers
2.1 Global Urological Cancer Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Urological Cancer Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Urological Cancer Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Urological Cancer Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Urological Cancer Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Urological Cancer Drugs, Product Type & Application
2.7 Urological Cancer Drugs Market Competitive Situation and Trends
2.7.1 Urological Cancer Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Urological Cancer Drugs Players Market Share by Revenue
2.7.3 Global Urological Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Urological Cancer Drugs Retrospective Market Scenario by Region
3.1 Global Urological Cancer Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Urological Cancer Drugs Global Urological Cancer Drugs Sales by Region: 2019-2030
3.2.1 Global Urological Cancer Drugs Sales by Region: 2019-2024
3.2.2 Global Urological Cancer Drugs Sales by Region: 2025-2030
3.3 Global Urological Cancer Drugs Global Urological Cancer Drugs Revenue by Region: 2019-2030
3.3.1 Global Urological Cancer Drugs Revenue by Region: 2019-2024
3.3.2 Global Urological Cancer Drugs Revenue by Region: 2025-2030
3.4 North America Urological Cancer Drugs Market Facts & Figures by Country
3.4.1 North America Urological Cancer Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Urological Cancer Drugs Sales by Country (2019-2030)
3.4.3 North America Urological Cancer Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Urological Cancer Drugs Market Facts & Figures by Country
3.5.1 Europe Urological Cancer Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Urological Cancer Drugs Sales by Country (2019-2030)
3.5.3 Europe Urological Cancer Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Urological Cancer Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Urological Cancer Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Urological Cancer Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Urological Cancer Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Urological Cancer Drugs Market Facts & Figures by Country
3.7.1 Latin America Urological Cancer Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Urological Cancer Drugs Sales by Country (2019-2030)
3.7.3 Latin America Urological Cancer Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Urological Cancer Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Urological Cancer Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Urological Cancer Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Urological Cancer Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Urological Cancer Drugs Sales by Type (2019-2030)
4.1.1 Global Urological Cancer Drugs Sales by Type (2019-2024)
4.1.2 Global Urological Cancer Drugs Sales by Type (2025-2030)
4.1.3 Global Urological Cancer Drugs Sales Market Share by Type (2019-2030)
4.2 Global Urological Cancer Drugs Revenue by Type (2019-2030)
4.2.1 Global Urological Cancer Drugs Revenue by Type (2019-2024)
4.2.2 Global Urological Cancer Drugs Revenue by Type (2025-2030)
4.2.3 Global Urological Cancer Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Urological Cancer Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Urological Cancer Drugs Sales by Application (2019-2030)
5.1.1 Global Urological Cancer Drugs Sales by Application (2019-2024)
5.1.2 Global Urological Cancer Drugs Sales by Application (2025-2030)
5.1.3 Global Urological Cancer Drugs Sales Market Share by Application (2019-2030)
5.2 Global Urological Cancer Drugs Revenue by Application (2019-2030)
5.2.1 Global Urological Cancer Drugs Revenue by Application (2019-2024)
5.2.2 Global Urological Cancer Drugs Revenue by Application (2025-2030)
5.2.3 Global Urological Cancer Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Urological Cancer Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Urological Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Urological Cancer Drugs Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Urological Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer Urological Cancer Drugs Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Johnson & Johnson
6.3.1 Johnson & Johnson Corporation Information
6.3.2 Johnson & Johnson Description and Business Overview
6.3.3 Johnson & Johnson Urological Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Johnson & Johnson Urological Cancer Drugs Product Portfolio
6.3.5 Johnson & Johnson Recent Developments/Updates
6.4 AstraZeneca
6.4.1 AstraZeneca Corporation Information
6.4.2 AstraZeneca Description and Business Overview
6.4.3 AstraZeneca Urological Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 AstraZeneca Urological Cancer Drugs Product Portfolio
6.4.5 AstraZeneca Recent Developments/Updates
6.5 Astellas
6.5.1 Astellas Corporation Information
6.5.2 Astellas Description and Business Overview
6.5.3 Astellas Urological Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Astellas Urological Cancer Drugs Product Portfolio
6.5.5 Astellas Recent Developments/Updates
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Urological Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Bristol-Myers Squibb Urological Cancer Drugs Product Portfolio
6.6.5 Bristol-Myers Squibb Recent Developments/Updates
6.7 Abbott Laboratories
6.6.1 Abbott Laboratories Corporation Information
6.6.2 Abbott Laboratories Description and Business Overview
6.6.3 Abbott Laboratories Urological Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Abbott Laboratories Urological Cancer Drugs Product Portfolio
6.7.5 Abbott Laboratories Recent Developments/Updates
6.8 Celgene Corporation
6.8.1 Celgene Corporation Corporation Information
6.8.2 Celgene Corporation Description and Business Overview
6.8.3 Celgene Corporation Urological Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Celgene Corporation Urological Cancer Drugs Product Portfolio
6.8.5 Celgene Corporation Recent Developments/Updates
6.9 Dendreon Corporation
6.9.1 Dendreon Corporation Corporation Information
6.9.2 Dendreon Corporation Description and Business Overview
6.9.3 Dendreon Corporation Urological Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Dendreon Corporation Urological Cancer Drugs Product Portfolio
6.9.5 Dendreon Corporation Recent Developments/Updates
6.10 Ferring Pharmaceuticals
6.10.1 Ferring Pharmaceuticals Corporation Information
6.10.2 Ferring Pharmaceuticals Description and Business Overview
6.10.3 Ferring Pharmaceuticals Urological Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Ferring Pharmaceuticals Urological Cancer Drugs Product Portfolio
6.10.5 Ferring Pharmaceuticals Recent Developments/Updates
6.11 GlaxoSmithKline
6.11.1 GlaxoSmithKline Corporation Information
6.11.2 GlaxoSmithKline Urological Cancer Drugs Description and Business Overview
6.11.3 GlaxoSmithKline Urological Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 GlaxoSmithKline Urological Cancer Drugs Product Portfolio
6.11.5 GlaxoSmithKline Recent Developments/Updates
6.12 Indevus Pharmaceuticals Inc
6.12.1 Indevus Pharmaceuticals Inc Corporation Information
6.12.2 Indevus Pharmaceuticals Inc Urological Cancer Drugs Description and Business Overview
6.12.3 Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Indevus Pharmaceuticals Inc Urological Cancer Drugs Product Portfolio
6.12.5 Indevus Pharmaceuticals Inc Recent Developments/Updates
6.13 Ipsen
6.13.1 Ipsen Corporation Information
6.13.2 Ipsen Urological Cancer Drugs Description and Business Overview
6.13.3 Ipsen Urological Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Ipsen Urological Cancer Drugs Product Portfolio
6.13.5 Ipsen Recent Developments/Updates
6.14 Roche Healthcare
6.14.1 Roche Healthcare Corporation Information
6.14.2 Roche Healthcare Urological Cancer Drugs Description and Business Overview
6.14.3 Roche Healthcare Urological Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Roche Healthcare Urological Cancer Drugs Product Portfolio
6.14.5 Roche Healthcare Recent Developments/Updates
6.15 Sanofi S.A
6.15.1 Sanofi S.A Corporation Information
6.15.2 Sanofi S.A Urological Cancer Drugs Description and Business Overview
6.15.3 Sanofi S.A Urological Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Sanofi S.A Urological Cancer Drugs Product Portfolio
6.15.5 Sanofi S.A Recent Developments/Updates
6.16 Tolmar Inc
6.16.1 Tolmar Inc Corporation Information
6.16.2 Tolmar Inc Urological Cancer Drugs Description and Business Overview
6.16.3 Tolmar Inc Urological Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Tolmar Inc Urological Cancer Drugs Product Portfolio
6.16.5 Tolmar Inc Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Urological Cancer Drugs Industry Chain Analysis
7.2 Urological Cancer Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Urological Cancer Drugs Production Mode & Process
7.4 Urological Cancer Drugs Sales and Marketing
7.4.1 Urological Cancer Drugs Sales Channels
7.4.2 Urological Cancer Drugs Distributors
7.5 Urological Cancer Drugs Customers
8 Urological Cancer Drugs Market Dynamics
8.1 Urological Cancer Drugs Industry Trends
8.2 Urological Cancer Drugs Market Drivers
8.3 Urological Cancer Drugs Market Challenges
8.4 Urological Cancer Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Urological Cancer Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Urological Cancer Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Urological Cancer Drugs Market Competitive Situation by Manufacturers in 2023
Table 4. Global Urological Cancer Drugs Sales (K Pcs) of Key Manufacturers (2019-2024)
Table 5. Global Urological Cancer Drugs Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Urological Cancer Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Urological Cancer Drugs Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Urological Cancer Drugs Average Price (USD/Pcs) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Urological Cancer Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Urological Cancer Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Urological Cancer Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Urological Cancer Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Urological Cancer Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Urological Cancer Drugs as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Urological Cancer Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Urological Cancer Drugs Sales by Region (2019-2024) & (K Pcs)
Table 18. Global Urological Cancer Drugs Sales Market Share by Region (2019-2024)
Table 19. Global Urological Cancer Drugs Sales by Region (2025-2030) & (K Pcs)
Table 20. Global Urological Cancer Drugs Sales Market Share by Region (2025-2030)
Table 21. Global Urological Cancer Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Urological Cancer Drugs Revenue Market Share by Region (2019-2024)
Table 23. Global Urological Cancer Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Urological Cancer Drugs Revenue Market Share by Region (2025-2030)
Table 25. North America Urological Cancer Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Urological Cancer Drugs Sales by Country (2019-2024) & (K Pcs)
Table 27. North America Urological Cancer Drugs Sales by Country (2025-2030) & (K Pcs)
Table 28. North America Urological Cancer Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Urological Cancer Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Urological Cancer Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Urological Cancer Drugs Sales by Country (2019-2024) & (K Pcs)
Table 32. Europe Urological Cancer Drugs Sales by Country (2025-2030) & (K Pcs)
Table 33. Europe Urological Cancer Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Urological Cancer Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Urological Cancer Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Urological Cancer Drugs Sales by Region (2019-2024) & (K Pcs)
Table 37. Asia Pacific Urological Cancer Drugs Sales by Region (2025-2030) & (K Pcs)
Table 38. Asia Pacific Urological Cancer Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Urological Cancer Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Urological Cancer Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Urological Cancer Drugs Sales by Country (2019-2024) & (K Pcs)
Table 42. Latin America Urological Cancer Drugs Sales by Country (2025-2030) & (K Pcs)
Table 43. Latin America Urological Cancer Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Urological Cancer Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Urological Cancer Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Urological Cancer Drugs Sales by Country (2019-2024) & (K Pcs)
Table 47. Middle East & Africa Urological Cancer Drugs Sales by Country (2025-2030) & (K Pcs)
Table 48. Middle East & Africa Urological Cancer Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Urological Cancer Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Urological Cancer Drugs Sales (K Pcs) by Type (2019-2024)
Table 51. Global Urological Cancer Drugs Sales (K Pcs) by Type (2025-2030)
Table 52. Global Urological Cancer Drugs Sales Market Share by Type (2019-2024)
Table 53. Global Urological Cancer Drugs Sales Market Share by Type (2025-2030)
Table 54. Global Urological Cancer Drugs Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Urological Cancer Drugs Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Urological Cancer Drugs Revenue Market Share by Type (2019-2024)
Table 57. Global Urological Cancer Drugs Revenue Market Share by Type (2025-2030)
Table 58. Global Urological Cancer Drugs Price (USD/Pcs) by Type (2019-2024)
Table 59. Global Urological Cancer Drugs Price (USD/Pcs) by Type (2025-2030)
Table 60. Global Urological Cancer Drugs Sales (K Pcs) by Application (2019-2024)
Table 61. Global Urological Cancer Drugs Sales (K Pcs) by Application (2025-2030)
Table 62. Global Urological Cancer Drugs Sales Market Share by Application (2019-2024)
Table 63. Global Urological Cancer Drugs Sales Market Share by Application (2025-2030)
Table 64. Global Urological Cancer Drugs Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Urological Cancer Drugs Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Urological Cancer Drugs Revenue Market Share by Application (2019-2024)
Table 67. Global Urological Cancer Drugs Revenue Market Share by Application (2025-2030)
Table 68. Global Urological Cancer Drugs Price (USD/Pcs) by Application (2019-2024)
Table 69. Global Urological Cancer Drugs Price (USD/Pcs) by Application (2025-2030)
Table 70. Novartis Corporation Information
Table 71. Novartis Description and Business Overview
Table 72. Novartis Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 73. Novartis Urological Cancer Drugs Product
Table 74. Novartis Recent Developments/Updates
Table 75. Pfizer Corporation Information
Table 76. Pfizer Description and Business Overview
Table 77. Pfizer Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 78. Pfizer Urological Cancer Drugs Product
Table 79. Pfizer Recent Developments/Updates
Table 80. Johnson & Johnson Corporation Information
Table 81. Johnson & Johnson Description and Business Overview
Table 82. Johnson & Johnson Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 83. Johnson & Johnson Urological Cancer Drugs Product
Table 84. Johnson & Johnson Recent Developments/Updates
Table 85. AstraZeneca Corporation Information
Table 86. AstraZeneca Description and Business Overview
Table 87. AstraZeneca Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 88. AstraZeneca Urological Cancer Drugs Product
Table 89. AstraZeneca Recent Developments/Updates
Table 90. Astellas Corporation Information
Table 91. Astellas Description and Business Overview
Table 92. Astellas Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 93. Astellas Urological Cancer Drugs Product
Table 94. Astellas Recent Developments/Updates
Table 95. Bristol-Myers Squibb Corporation Information
Table 96. Bristol-Myers Squibb Description and Business Overview
Table 97. Bristol-Myers Squibb Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 98. Bristol-Myers Squibb Urological Cancer Drugs Product
Table 99. Bristol-Myers Squibb Recent Developments/Updates
Table 100. Abbott Laboratories Corporation Information
Table 101. Abbott Laboratories Description and Business Overview
Table 102. Abbott Laboratories Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 103. Abbott Laboratories Urological Cancer Drugs Product
Table 104. Abbott Laboratories Recent Developments/Updates
Table 105. Celgene Corporation Corporation Information
Table 106. Celgene Corporation Description and Business Overview
Table 107. Celgene Corporation Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 108. Celgene Corporation Urological Cancer Drugs Product
Table 109. Celgene Corporation Recent Developments/Updates
Table 110. Dendreon Corporation Corporation Information
Table 111. Dendreon Corporation Description and Business Overview
Table 112. Dendreon Corporation Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 113. Dendreon Corporation Urological Cancer Drugs Product
Table 114. Dendreon Corporation Recent Developments/Updates
Table 115. Ferring Pharmaceuticals Corporation Information
Table 116. Ferring Pharmaceuticals Description and Business Overview
Table 117. Ferring Pharmaceuticals Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 118. Ferring Pharmaceuticals Urological Cancer Drugs Product
Table 119. Ferring Pharmaceuticals Recent Developments/Updates
Table 120. GlaxoSmithKline Corporation Information
Table 121. GlaxoSmithKline Description and Business Overview
Table 122. GlaxoSmithKline Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 123. GlaxoSmithKline Urological Cancer Drugs Product
Table 124. GlaxoSmithKline Recent Developments/Updates
Table 125. Indevus Pharmaceuticals Inc Corporation Information
Table 126. Indevus Pharmaceuticals Inc Description and Business Overview
Table 127. Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 128. Indevus Pharmaceuticals Inc Urological Cancer Drugs Product
Table 129. Indevus Pharmaceuticals Inc Recent Developments/Updates
Table 130. Ipsen Corporation Information
Table 131. Ipsen Description and Business Overview
Table 132. Ipsen Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 133. Ipsen Urological Cancer Drugs Product
Table 134. Ipsen Recent Developments/Updates
Table 135. Roche Healthcare Corporation Information
Table 136. Roche Healthcare Description and Business Overview
Table 137. Roche Healthcare Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 138. Roche Healthcare Urological Cancer Drugs Product
Table 139. Roche Healthcare Recent Developments/Updates
Table 140. Sanofi S.A Corporation Information
Table 141. Sanofi S.A Description and Business Overview
Table 142. Sanofi S.A Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 143. Sanofi S.A Urological Cancer Drugs Product
Table 144. Sanofi S.A Recent Developments/Updates
Table 145. Tolmar Inc Corporation Information
Table 146. Tolmar Inc Description and Business Overview
Table 147. Tolmar Inc Urological Cancer Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 148. Tolmar Inc Urological Cancer Drugs Product
Table 149. Tolmar Inc Recent Developments/Updates
Table 150. Key Raw Materials Lists
Table 151. Raw Materials Key Suppliers Lists
Table 152. Urological Cancer Drugs Distributors List
Table 153. Urological Cancer Drugs Customers List
Table 154. Urological Cancer Drugs Market Trends
Table 155. Urological Cancer Drugs Market Drivers
Table 156. Urological Cancer Drugs Market Challenges
Table 157. Urological Cancer Drugs Market Restraints
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Urological Cancer Drugs
Figure 2. Global Urological Cancer Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Urological Cancer Drugs Market Share by Type in 2023 & 2030
Figure 4. Tablets Product Picture
Figure 5. Injection Product Picture
Figure 6. Global Urological Cancer Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Urological Cancer Drugs Market Share by Application in 2023 & 2030
Figure 8. Prostate Cancer
Figure 9. Bladder Cancer
Figure 10. Kidney Cancer
Figure 11. Testicular Cancer
Figure 12. Others
Figure 13. Global Urological Cancer Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Urological Cancer Drugs Market Size (2019-2030) & (US$ Million)
Figure 15. Global Urological Cancer Drugs Sales (2019-2030) & (K Pcs)
Figure 16. Global Urological Cancer Drugs Average Price (USD/Pcs) & (2019-2030)
Figure 17. Urological Cancer Drugs Report Years Considered
Figure 18. Urological Cancer Drugs Sales Share by Manufacturers in 2023
Figure 19. Global Urological Cancer Drugs Revenue Share by Manufacturers in 2023
Figure 20. The Global 5 and 10 Largest Urological Cancer Drugs Players: Market Share by Revenue in 2023
Figure 21. Urological Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 22. Global Urological Cancer Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 23. North America Urological Cancer Drugs Sales Market Share by Country (2019-2030)
Figure 24. North America Urological Cancer Drugs Revenue Market Share by Country (2019-2030)
Figure 25. U.S. Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Canada Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Europe Urological Cancer Drugs Sales Market Share by Country (2019-2030)
Figure 28. Europe Urological Cancer Drugs Revenue Market Share by Country (2019-2030)
Figure 29. Germany Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. France Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. U.K. Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Italy Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Russia Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Asia Pacific Urological Cancer Drugs Sales Market Share by Region (2019-2030)
Figure 35. Asia Pacific Urological Cancer Drugs Revenue Market Share by Region (2019-2030)
Figure 36. China Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Japan Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. South Korea Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. India Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Australia Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Taiwan Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Indonesia Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Thailand Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Malaysia Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Philippines Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Latin America Urological Cancer Drugs Sales Market Share by Country (2019-2030)
Figure 47. Latin America Urological Cancer Drugs Revenue Market Share by Country (2019-2030)
Figure 48. Mexico Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Brazil Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Argentina Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Middle East & Africa Urological Cancer Drugs Sales Market Share by Country (2019-2030)
Figure 52. Middle East & Africa Urological Cancer Drugs Revenue Market Share by Country (2019-2030)
Figure 53. Turkey Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Saudi Arabia Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. U.A.E Urological Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Global Sales Market Share of Urological Cancer Drugs by Type (2019-2030)
Figure 57. Global Revenue Market Share of Urological Cancer Drugs by Type (2019-2030)
Figure 58. Global Urological Cancer Drugs Price (USD/Pcs) by Type (2019-2030)
Figure 59. Global Sales Market Share of Urological Cancer Drugs by Application (2019-2030)
Figure 60. Global Revenue Market Share of Urological Cancer Drugs by Application (2019-2030)
Figure 61. Global Urological Cancer Drugs Price (USD/Pcs) by Application (2019-2030)
Figure 62. Urological Cancer Drugs Value Chain
Figure 63. Urological Cancer Drugs Production Process
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Distributors Profiles
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
